📊 Score Breakdown
Offering Ability
50
Cash Runway
10
Float Risk
40
Warrant Exposure
70
Convertible Debt—
🌦️ Dilution Forecast
🌥️
Advisory
Moderate dilution signals present
36%
📜 Warrant Exercise
40%
• Significant warrants: 22% of shares outstanding
• Elevated warrant risk score (70/100)
📉 Score Deterioration
40%
• Score rose 20 points recently (worsening)
💰 Capital Raise
20%
• Active shelf registration ($85M, 44% of market cap)
💹 Market Data
Market Cap$193.41M
Shares Outstanding14.42M
Float9.36M
Cash$113.97M
Debt$42.88M
Short InterestN/A
🏛 Institutional Holdings
QoQ: ↓ 15.2% shares (2025Q4 vs prior)
83 institutional holders · 8.49M shares
#1
Atlas Venture Life Science Advisors, LLC
1.14M shares
#2
NEA Management Company, LLC
1.09M shares
#3
Lynx1 Capital Management LP
677.9K shares
+ 17 more holders Sign up free to view →
📉 Short Interest
Short Interest1.19M
Days to Cover11.4
% of Float12.8%
FINRA data as of May 15, 2026
📁 Recent SEC Activity
xbrl
XBRL CONVERTIBLE
Dec 31, 2018
S-3
SHELF
Mar 13, 2026
4
INSIDER TRANSACTION
Mar 12, 2026
4
INSIDER TRANSACTION
Mar 12, 2026
4
INSIDER TRANSACTION
Mar 12, 2026
Full SEC filing analysis available with free account →
📰 Recent News
No recent news
🔬 More Research for KRRO
📊 KRRO FDA Catalyst Timeline & Biotech Grade — BiotechSigns
📡 KRRO Signal Convergence & Dark Pool Activity — StonkWhisper
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.